A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Colesevelam (Primary)
- Indications Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 13 Feb 2019 According to an Ironwood Pharmaceuticals media release, data from this trial is expected in the second half of 2020.
- 15 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 21 Jun 2018 Status changed from not yet recruiting to recruiting, according to an Ironwood Pharmaceuticals media release.